Abstract
Abiraterone and enzalutamide are novel hormonal treatments for castration-resistant prostate cancer that have been demonstrated to improve overall survival. Although their mechanisms are different, the clinical efficacy of these drugs appears very similar. Elucidating an appropriate treatment sequence of these therapies is important for maximizing the clinical benefit of castration-resistant prostate cancer patients. Currently, there is a trend to use these novel hormonal therapies before chemotherapy because of better tolerability, especially for the patients with long duration to resistance to first-line androgen deprivation therapy. Recent reports have shown that the abiraterone-to-enzalutamide sequence might have more favorable efficacy in terms of combined prostate-specific antigen progression-free survival than the enzalutamide-to-abiraterone sequence. However, there was no significant difference in overall survival. Based on these studies, the optimal sequence of these novel hormonal therapies is discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.
Mohler JL. Castration-recurrent prostate cancer is not androgen-independent. Adv Exp Med Biol. 2008;617:223–34.
Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.
Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.
Flaig TW, Potluri RC, Ng Y, Todd MB, Mehra M. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data. Cancer Med. 2016;5:182–91.
Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028–38.
Antonarakis ESLC, Luber B. Clinical significance of AR-V7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol. 2017;35(19):2149–56.
Antonarakis ES, Lu C, Luber B, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 2015;1:582–91.
Onstenk W, Sieuwerts AM, Kraan J, et al. Efficacy of Cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur Urol. 2015;68:939–45.
Scher HI, Lu D, Schreiber NA, et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol. 2016;2:1441–9.
Loriot Y, Eymard JC, Patrikidou A, et al. Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer. Eur J Cancer. 2015;51:1946–52.
van Soest RJ, Templeton AJ, Vera-Badillo FE, et al. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann Oncol. 2015;26:743–9.
Terada N, Akamatsu S, Okada Y, et al. Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study. Int J Clin Oncol. 2016;21:1155–61.
Terada N, Maughan BL, Akamatsu S, et al. Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: the Kyoto-Baltimore collaboration. Int J Urol. 2017;24:441–8.
Lorente D, Mateo J, Perez-Lopez R, de Bono JS, Attard G. Sequencing of agents in castration-resistant prostate cancer. Lancet Oncol. 2015;16:e279–92.
Maughan BL, Luber B, Nadal R, Antonarakis ES. Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: a retrospective study. Prostate. 2017;77:33–40.
Miyake H, Hara T, Terakawa T, Ozono S, Fujisawa M. Comparative assessment of clinical outcomes between abiraterone acetate and enzalutamide in patients with docetaxel-naive metastatic castration-resistant prostate cancer: experience in real-world clinical practice in Japan. Clin Genitourin Cancer. 2017;15:313–9.
Handy CE, Antonarakis ES. Sequencing treatment for castration-resistant prostate cancer. Curr Treat Options in Oncol. 2016;17:64.
Acknowledgments
We thank Edanz Group (www.edanzediting.com) for editing a draft of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Terada, N. (2018). Optimization of Sequential AR Targeted Therapy for CRPC. In: Arai, Y., Ogawa, O. (eds) Hormone Therapy and Castration Resistance of Prostate Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-10-7013-6_23
Download citation
DOI: https://doi.org/10.1007/978-981-10-7013-6_23
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-7012-9
Online ISBN: 978-981-10-7013-6
eBook Packages: MedicineMedicine (R0)